VEGFR-2 inhibitor

DRUG CLASS:

VEGFR-2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + ramucirumab Sensitive: C3 – Early Trials J Clin Oncol - 3 days (New C3) trastuzumab + ramucirumab Sensitive : C3 J Clin Oncol - 3d	trastuzumab + ramucirumab Sensitive: C3 – Early Trials J Clin Oncol - 3 days trastuzumab + ramucirumab Sensitive : C3 J Clin Oncol - 3 days - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	ramucirumab Sensitive: C2 – Inclusion Criteria ESMO Open - 1 week (New C3) ramucirumab Sensitive : C2 ESMO Open - 1wk	ramucirumab Sensitive: C2 – Inclusion Criteria ESMO Open - 1 week ramucirumab Sensitive : C2 ESMO Open - 1 week - (New C3)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	cetuximab + BMS-582664 Resistant: A2 - Guideline cetuximab + BMS-582664 Resistant : A2	cetuximab + BMS-582664 Resistant: A2 - Guideline cetuximab + BMS-582664 Resistant : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	rivoceranib Sensitive: B - Late Trials rivoceranib Sensitive : B	rivoceranib Sensitive: B - Late Trials rivoceranib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
TP53 exon 8 mutation	Non Small Cell Lung Cancer	TP53 exon 8 mutation	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
VEGFD elevation	Colorectal Cancer	VEGFD elevation	Colorectal Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B

VEGFR-2 inhibitor

VEGFR-2 inhibitor

Associations(155)

Associations
(155)